{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:28:00Z","timestamp":1778761680503,"version":"3.51.4"},"reference-count":67,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Bacterial infections are common events that significantly impact the clinical course of patients with cirrhosis. As in the general population, infections caused by multi-drug-resistant organisms (MDROs) are progressively increasing in cirrhotic patients, accounting for up to 30\u201335% of all infections. Nosocomial acquisition and prior exposure to antimicrobial treatment or invasive procedures are well-known risk factors for MDRO infections. Several studies have demonstrated that infections due to MDROs have a poorer prognosis and higher rates of treatment failure, septic shock, and hospital mortality. Due to the increasing rate of antimicrobial resistance, the approach to empirical treatment in cirrhotic patients with life-threatening infections has become significantly more challenging. In order to ensure a prompt administration of effective antibiotic therapy while avoiding unnecessary antibiotic exposure at the same time, it is of utmost importance to choose the correct antimicrobial therapy and administration schedule based on individual clinical characteristics and risk factors and rapidly adopt de-escalation strategies as soon as microbiological data are available. In the present paper, we aimed to provide an overview of the most frequent infections diagnosed in cirrhotic patients, the prevalence and impact of antimicrobial resistance, and potential therapeutic options in this population.<\/jats:p>","DOI":"10.3390\/antibiotics11020232","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T02:40:17Z","timestamp":1644547217000},"page":"232","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prevalence and Therapeutic Management of Infections by Multi-Drug-Resistant Organisms (MDROs) in Patients with Liver Cirrhosis: A Narrative Review"],"prefix":"10.3390","volume":"11","author":[{"given":"Lorenzo","family":"Onorato","sequence":"first","affiliation":[{"name":"Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-0573","authenticated-orcid":false,"given":"Caterina","family":"Monari","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Capuano","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierantonio","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-4949","authenticated-orcid":false,"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/gutjnl-2015-310275","article-title":"Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)","volume":"66","author":"Nahon","year":"2017","journal-title":"Gut"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMra2021808","article-title":"The Evolving Challenge of Infections in Cirrhosis","volume":"384","author":"Bajaj","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.14309\/ajg.0000000000000280","article-title":"Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients with Cirrhosis","volume":"114","author":"Bajaj","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/hep.28812","article-title":"Time trends in the health care burden and mortality of acute on chronic liver failure in the United States","volume":"64","author":"Allen","year":"2016","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2021.04.022","article-title":"Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis","volume":"75","author":"Villanueva","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2018.10.027","article-title":"Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe","volume":"70","author":"Prado","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1053\/j.gastro.2018.12.005","article-title":"Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide","volume":"156","author":"Piano","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"546e1","DOI":"10.1016\/j.cmi.2017.08.001","article-title":"A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients","volume":"24","author":"Bartoletti","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/apt.12797","article-title":"Prevalence and in-hospital mortality trends of infections among patients with cirrhosis: A nationwide study of hospitalised patients in the United States","volume":"40","author":"Singal","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/17474124.2019.1644167","article-title":"Primary and secondary prophylaxis of spontaneous bacterial peritonitis: Current state of the art","volume":"13","author":"Facciorusso","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.27077","article-title":"Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures","volume":"60","author":"Bajaj","year":"2014","journal-title":"Hepatology"},{"key":"ref_12","first-page":"S101","article-title":"Management of bacterial infections in cirrhosis","volume":"56","author":"Gustot","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11938-019-00229-2","article-title":"Infections in Cirrhosis","volume":"17","author":"Ekpanyapong","year":"2019","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hung, T.H., Tseng, C.W., Hsieh, Y.H., Tseng, K.C., Tsai, C.C., and Tsai, C.C. (2013). High mortality of pneumonia in cirrhotic patients with ascites. BMC Gastroenterol., 13.","DOI":"10.1186\/1471-230X-13-25"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/MD.0b013e318210504c","article-title":"Community-acquired pneumonia in patients with liver cirrhosis: Clinical features, outcomes, and usefulness of severity scores","volume":"90","author":"Viasus","year":"2011","journal-title":"Medicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1055\/s-0035-1562903","article-title":"Voriconazole: How to Use This Antifungal Agent and What to Expect","volume":"36","author":"Malani","year":"2015","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.diagmicrobio.2008.05.016","article-title":"Necrotizing fasciitis in patients with liver cirrhosis: Predominance of monomicrobial Gram-negative bacillary infections","volume":"62","author":"Lee","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2014.01.024","article-title":"Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013","volume":"60","author":"Jalan","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aohep.2019.09.011","article-title":"Bacterial infections in cirrhosis: Current treatment","volume":"19","year":"2020","journal-title":"Ann. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.25532","article-title":"Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study","volume":"55","author":"Acevedo","year":"2012","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jhep.2014.03.021","article-title":"Epidemiology and outcomes of bloodstream infection in patients with cirrhosis","volume":"61","author":"Bartoletti","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.clinre.2019.10.003","article-title":"Management of infections in patients with cirrhosis in the context of increasing therapeutic resistance: A systematic review","volume":"44","author":"Allaire","year":"2020","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kakoullis, L., Papachristodoulou, E., Chra, P., and Panos, G. (2021). Mechanisms of antibiotic resistance in important gram-positive and gram-negative pathogens and novel antibiotic solutions. Antibiotics, 10.","DOI":"10.3390\/antibiotics10040415"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jubeh, B., Breijyeh, Z., and Karaman, R. (2020). Resistance of gram-positive bacteria to current antibacterial agents and overcoming approaches. Molecules, 25.","DOI":"10.3390\/molecules25122888"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.jhep.2020.11.010","article-title":"Management of bacterial and fungal infections in cirrhosis: The MDRO challenge","volume":"75","author":"Piano","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"De Angelis, G., Del Giacomo, P., Posteraro, B., Sanguinetti, M., and Tumbarello, M. (2020). Molecular mechanisms, epidemiology, and clinical importance of \u03b2-lactam resistance in enterobacteriaceae. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21145090"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"a025239","DOI":"10.1101\/cshperspect.a025239","article-title":"\u03b2-Lactamases: A focus on current challenges","volume":"7","author":"Bonomo","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1098\/rstb.1980.0049","article-title":"The structure of beta-lactamases","volume":"289","author":"Ambler","year":"1980","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.39.6.1211","article-title":"A functional classification scheme for \u03b2-lactamases and its correlation with molecular structure","volume":"39","author":"Bush","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e01076-18","DOI":"10.1128\/AAC.01076-18","article-title":"Past and present perspectives on \u03b2-lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between \u03b2-lactamases and new \u03b2-lactamase inhibitors","volume":"17","author":"Bush","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"dlab092","DOI":"10.1093\/jacamr\/dlab092","article-title":"Extended-spectrum \u03b2-lactamases: An update on their characteristics, epidemiology and detection","volume":"3","author":"Castanheira","year":"2021","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e00079-17","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-beta-lactamase-, ampC-, and carbapenemase-producing enterobacteriaceae","volume":"31","author":"Machuca","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2174\/1389450117666160310144501","article-title":"Structural and Functional Aspects of Class A Carbapenemases","volume":"17","author":"Naas","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1128\/CMR.00021-21","article-title":"New \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e00031-19","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijmm.2011.10.001","article-title":"Structure and function of OprD protein in Pseudomonas aeruginosa: From antibiotic resistance to novel therapies","volume":"302","author":"Li","year":"2012","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/jac\/46.6.885","article-title":"Influence of the MexA-MexB-OprM multidrug efflux system on expression of the MexC-MexD-OprJ and MexE-MexF-OprN multidrug efflux systems in Pseudomonas aeruginosa","volume":"46","author":"Li","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/CMR.00117-14","article-title":"The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria","volume":"28","author":"Li","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of ampc","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1128\/AAC.00680-12","article-title":"Pan-\u03b2-lactam resistance development in Pseudomonas aeruginosa clinical strains: Molecular mechanisms, penicillin-binding protein profiles, and binding affinities","volume":"56","author":"Beceiro","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1128\/AAC.01581-12","article-title":"Quantitative contributions of target alteration and decreased drug accumulation to pseudomonas aeruginosa fluoroquinolone resistance","volume":"57","author":"Bruchmann","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fmicb.2014.00643","article-title":"Mechanisms of polymyxin resistance: Acquired and intrinsic resistance in bacteria","volume":"5","author":"Olaitan","year":"2014","journal-title":"Front. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kyriakidis, I., Vasileiou, E., Pana, Z.D., and Tragiannidis, A. (2021). Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens, 10.","DOI":"10.3390\/pathogens10030373"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nrmicro1789","article-title":"An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii","volume":"5","author":"Dijkshoorn","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Vrancianu, C.O., Gheorghe, I., Czobor, I.B., and Chifiriuc, M.C. (2020). Antibiotic resistance profiles, molecular mechanisms and innovative treatment strategies of Acinetobacter baumannii. Microorganisms, 8.","DOI":"10.3390\/microorganisms8060935"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","article-title":"Time to Treatment and Mortality during Mandated Emergency Care for Sepsis","volume":"376","author":"Seymour","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_49","first-page":"176","article-title":"V Antimicrobials: Access and sustainable effectiveness 2. Understanding the mechanisms and drivers of antimicrobial resistance","volume":"387","author":"Holmes","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MEG.0000000000001057","article-title":"Are third-generation cephalosporins still the empirical antibiotic treatment of community-Acquired spontaneous bacterial peritonitis? A systematic review and meta-Analysis","volume":"30","author":"Fiore","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/hep.27941","article-title":"The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial","volume":"63","author":"Piano","year":"2016","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia","volume":"50","author":"Torres","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/cid\/ciw504","article-title":"Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1473-3099(20)30523-5","article-title":"Effectiveness of adjunctive clindamycin in \u03b2-lactam antibiotic-treated patients with invasive \u03b2-haemolytic streptococcal infections in US hospitals: A retrospective multicentre cohort study","volume":"21","author":"Babiker","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/clinids\/18.3.324","article-title":"Pharmacological, toxicologic, and microbiological considerations in the choice of initial antibiotic therapy for serious infections in patients with cirrhosis of the liver","volume":"18","author":"Westphal","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/17512433.2016.1135733","article-title":"Variations of pharmacokinetics of drugs in patients with cirrhosis","volume":"9","author":"Pena","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-020-00919-6","article-title":"Prolonged Versus Intermittent Infusion of \u03b2-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models","volume":"59","author":"Dhaese","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","article-title":"Continuous versus intermittent \u03b2-lactam infusion in severe sepsis: A meta-analysis of individual patient data from randomized trials","volume":"194","author":"Roberts","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/cid\/ciz032","article-title":"Extended infusion of \u03b2-lactams for bloodstream infection in patients with liver cirrhosis: An observational multicenter study","volume":"69","author":"Bartoletti","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1093\/jac\/dkaa362","article-title":"Meropenem population pharmacokinetics in patients with decompensated cirrhosis and severe infections","volume":"75","author":"Bastida","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","article-title":"Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/0018578718772266","article-title":"Evaluation of Vancomycin Dosing in Patients With Cirrhosis: Beginning De-Liver-ations about a New Nomogram","volume":"54","author":"Regal","year":"2019","journal-title":"Hosp. Pharm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/FTD.0000000000000665","article-title":"Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity","volume":"41","author":"Luque","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cmi.2016.05.023","article-title":"Antibiotic de-escalation for bloodstream infections and pneumonia: Systematic review and meta-analysis","volume":"22","author":"Paul","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00134-019-05866-w","article-title":"Antimicrobial de-escalation in critically ill patients: A position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP)","volume":"46","author":"Tabah","year":"2020","journal-title":"Intensiv. Care Med."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/2\/232\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:18:09Z","timestamp":1760134689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/2\/232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["antibiotics11020232"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11020232","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]}}}